CureVac N.V.

94.79-3.41-3.47%Vol 789.49K1Y Perf 69.14%
Jun 16th, 2021 16:00 DELAYED
BID94.57 ASK94.79
Open98.76 Previous Close98.20
Pre-Market- After-Market-
 - -  - -%
Target Price
47.50 
Analyst Rating
— — 0.00
Potential %
-49.89 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     46.81
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap17.72B 
Earnings Rating
Price Range Ratio 52W %
50.70 
Earnings Date
-

Today's Price Range

93.92101.00

52W Range

36.15151.80

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-3.10%
1 Month
-15.21%
3 Months
-0.89%
6 Months
-9.14%
1 Year
69.14%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CVAC94.79-3.4100-3.47
AAPL130.46-1.3300-1.01
GOOG2 511.35-16.0700-0.64
MSFT259.43-1.4700-0.56
XOM60.40-1.5900-2.56
WFC41.75-1.0400-2.43
JNJ161.98-3.2400-1.96
FB329.66-6.8500-2.04
GE12.78-0.2200-1.69
JPM147.92-3.8400-2.53
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume789.49K
Shares Outstanding186.91M
Trades Count13.13K
Dollar Volume111.95M
Avg. Volume941.26K
Avg. Weekly Volume745.09K
Avg. Monthly Volume768.24K
Avg. Quarterly Volume1.02M

CureVac N.V. (NASDAQ: CVAC) stock closed at 61.94 per share at the end of the most recent trading day (a -3.47% change compared to the prior day closing price) with a volume of 6.81M shares and market capitalization of 17.72B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 484 people. CureVac N.V. CEO is Franz-Werner Haas.

The one-year performance of CureVac N.V. stock is 69.14%, while year-to-date (YTD) performance is 16.92%. CVAC stock has a five-year performance of %. Its 52-week range is between 36.15 and 151.8, which gives CVAC stock a 52-week price range ratio of 50.70%

CureVac N.V. currently has a PE ratio of -82.30, a price-to-book (PB) ratio of 21.03, a price-to-sale (PS) ratio of 326.30, a price to cashflow ratio of 20.30, a PEG ratio of 2.32, a ROA of -15.73%, a ROC of -12.23% and a ROE of -38.63%. The company’s profit margin is -%, its EBITDA margin is -192.20%, and its revenue ttm is $55.83 Million , which makes it $0.30 revenue per share.

Of the last four earnings reports from CureVac N.V., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. CureVac N.V.’s next earnings report date is -.

The consensus rating of Wall Street analysts for CureVac N.V. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for CureVac N.V. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CureVac N.V. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CureVac N.V. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.52, ATR14 : 6.86, CCI20 : -153.11, Chaikin Money Flow : 0.12, MACD : -2.31, Money Flow Index : 41.04, ROC : -14.97, RSI : 39.05, STOCH (14,3) : 2.74, STOCH RSI : 0.00, UO : 36.53, Williams %R : -97.26), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CureVac N.V. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

CureVac N.V.

CureVac NV a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and pre-clinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.

CEO: Franz-Werner Haas

Telephone: +49 707198830

Address: Friedrich-Miescher-Strasse 15, Tubingen 72076, BW, DE

Number of employees: 484

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits